Completed PHASE1 NCT00002321
A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis
Sponsor: Chiron Corporation
Conditions
Cytomegalovirus Retinitis HIV Infections
Interventions
Aldesleukin
Updated 5 times since 2017 Last updated: Jun 23, 2005
Listed as NCT00002321, this PHASE1 trial focuses on Cytomegalovirus Retinitis and HIV Infections and remains completed. Sponsored by Chiron Corporation, it has been updated 5 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Chiron Corporation
Data source: NIH AIDS Clinical Trials Information Service
For direct contact, visit the study record on ClinicalTrials.gov .